abstract |
The present invention provides a modified immune cell (eg, a modified T cell) comprising an exogenous T cell receptor (TCR) specific to NY-ESO-1. The present invention provides a modified immune cell or a precursor thereof (eg, a modified T cell) comprising an exogenous TCR and a switch receptor. The present invention also provides a gene-edited cell such that one or both of an endogenous T cell receptor gene (eg, TRAC, TRBC) or an endogenous immune checkpoint gene (eg, PD-1 or TIM-3) Various performances were downgraded. |